An interview with lead investigator on full results from EMPEROR-Preserved Trial, which affirm that empagliflozin lowers the risk of CVD for heart failure in patients with HFpEF.
Welcome to this episode of Physician’s Weekly Podcast. My name is Dr Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly. This week I am recording this episode in the Italian alps, while attending the European Association of Urology Guidelines Panel meeting for Renal cell carcinoma, but we have 2 great in-depth interviews for you this week.
Later in this episode, Physician’s Weekly’s Editorial Director Chris Cole interviews Dr. J. Stacey Klutts, a medical microbiologist at Rush University, about his op-ed in the Tampa Bay Times comparing the Delta variant of SARS-CoV-2 to Gorilla Glue, which went viral. And yes, the pun was intended. Dr Klutts also tells us about exactly how the vaccine was developed and how the Delta variant is detected in patients. Did you know there are currently 13 subtypes of the Delta variant?
But first, we speak with the presenter at the European Society of Cardiology Annual Congress HOTLINE plenary talk, prof. Stefan Anker at the Charité Hospital in Berlin, Germany, about the full results of the EMPEROR-Preserved trial, which affirm that empagliflozin lowers the risk of cardiovascular death/hospitalization for heart failure in patients with heart failure and preserved ejection fraction (HFpEF), leading one expert to say this is “a big day for patients living with HFpEF, a big day for heart failure clinicians.”
The primary endpoint—a composite of CV death and hospitalization for heart failure—was reduced by a relative 21% in patients treated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor emagliflozin.
Published simultaneously online in the New England Journal of Medicine, these results represent the first trial to show unequivocal benefit of any drug on major heart failure outcomes in patients with heart failure and a preserved ejection fraction.